Your guide to peptide science
The education behind our peptide content
Dr. Greene is one of a select few pharmacists in the country to hold A4M Peptide Therapy Certification. He leads Evergreen's education program — translating current peptide science into rigorous, expert-level learning content. His focus is on education, not patient care: arming our community with depth, context, and the standards behind every topic we cover.
"Patients deserve peptides with expert physician guidance and licensed pharmacy quality-controls, not unregulated online gray market sources that put them at great risk."
Medically Reviewed articles

The Role of Glycine in Metabolic Health
Glycine isn't just an amino acid building block, it may support insulin sensitivity, antioxidant defense, and muscle preservation. Here's the research.

A Note From Evergreen on the July 2026 PCAC Peptide Review
Our statement on the FDA Pharmacy Compounding Advisory Committee's July 23–24, 2026 review of seven peptides, six recommended, one rejected. None are legal to compound today.

DSIP (Emideltide) Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted against recommending DSIP (Emideltide) for the FDA Section 503A Bulks List. Compounding is not authorized, here's where things stand.

Semax Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend Semax for the FDA Section 503A Bulks List. Compounding is not yet legal, here's exactly where things stand.

KPV Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend KPV for the FDA Section 503A Bulks List. Compounding is not yet legal, here's exactly where things stand.

TB-500 Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend TB-500 for the FDA Section 503A Bulks List. Compounding is not yet legal, here's exactly where things stand.

BPC-157 Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted 8-6 to recommend BPC-157 for the FDA Section 503A Bulks List. Compounding is not yet legal, here's exactly where things stand.

MOTS-c Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend MOTS-c for the FDA Section 503A Bulks List. Compounding is not yet legal, here's exactly where things stand.

Epitalon Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend Epitalon for the FDA Section 503A Bulks List. Compounding is not yet legal, here's exactly where things stand.

GLP-1 Weight Loss: The Complete Guide
Medically reviewed by Dr. Casey Greene

GLP-1 Weight Loss Treatment: How It Works
Medically reviewed by Dr. Casey Greene

Semaglutide vs. Tirzepatide: Full Comparison
Medically reviewed by Dr. Casey Greene

How Long Until My GLP-1 Starts Working?
Medically reviewed by Dr. Casey Greene

Why GLP-1 Medications Cause Nausea (and Fixes)
Medically reviewed by Dr. Casey Greene

What Are the Possible Side Effects of GLP-1s?
Medically reviewed by Dr. Casey Greene

Protect Muscle During GLP-1 Weight Loss
Medically reviewed by Dr. Casey Greene

What Is Metabolic Health?
Medically reviewed by Dr. Casey Greene

What Should I Expect From a GLP-1 Prescription?
Medically reviewed by Dr. Casey Greene

Why All Peptides Are Not Created Equal
Medically reviewed by Dr. Casey Greene